Ceftobiprole
Phase 1Terminated 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ventilator Associated Pneumonia
Conditions
Ventilator Associated Pneumonia
Trial Timeline
Oct 1, 2008 → Nov 1, 2009
NCT ID
NCT00771719About Ceftobiprole
Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Ventilator Associated Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00771719. Target conditions include Ventilator Associated Pneumonia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00965042 | Phase 1 | Completed |
| NCT00771524 | Phase 1 | Completed |
| NCT00771719 | Phase 1 | Terminated |
| NCT01026740 | Phase 1 | Completed |
Competing Products
9 competing products in Ventilator Associated Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Doripenem + Imipenem-Cilastatin + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/Tazobactam + Piperacillin/Tazobactam | Merck | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Vancomycin + Linezolid | Pfizer | Approved | 84 |
| anidulafungin | Pfizer | Phase 2 | 51 |
| Linezolid | Pfizer | Pre-clinical | 22 |
| aerosolized vancomycin or gentamicin | Nektar Therapeutics | Phase 2 | 47 |
| IC43 + Placebo | Valneva SE | Phase 2 | 47 |